Forum Archive Index - March 2000

[Glen Whiteman <quality.res.ltd@xtra.co.nz>]

Hi Nigel,
`The Speculator' in The Bulletin picked MIV at A18c, in Aug99.
At this stage I was just getting into the Aussie market, and was not
confident enough to buy in the mid 20s. I have since watched this stock
go higher and higher.
Do you think there is anymore growth in price left?
Glen.


Nigel McCarter wrote:
> 
> For those interested in the Biotech market should consider Medical
> innovations (MIV)
> The company's main product is a treatment for Psorias, (which Genesis is
> also trying to treat).  But MIV has developed an ointment which is now past
> clinical trial stage, whereas Genesis is using an immunisation approach.
> Immunisation is grand, except that the development period will be
> extensive.  In other words, MIV has a product just about ready for market
> (see press release below) GEN has a protracted period of trials and
> approvals yet to negotiate.
> I've attached the latest press release below.
> 
> (I hold MIV)
> 
> >    NOTE: Half Yearly Report 99-00 has been posted  today 15/03/2000 on the
> >MIL web site and is available as a PDF document for  viewing.   Below is
> >separate ASX release dated  15/03/2000.    SUBSTANTIAL IMPROVEMENT AS 6
> >MONTH LOSS HALVED; SALES SHOW STRONG GROWTH IN AUSTRALIA TRIALS OF SORAFIN
> >OVERSEAS PLANNED MIV halved the 6 month loss to December 99, compared with
> >the previous  corresponding December half-year; $370,000, compared with
> >$776,000. AUSTRALIAN SALES GROWTH This resulted from9% sales growth
> >overall, and reduced expenditure on trials  of MIV’s treatment for
> >psoriasis, SORAFIN, during the half year. Sales in Australia grew strongly;
> >up 16% on the previous period, reflecting  the success of the Strategic
> >Alliance with Clinical Data, which replaced  MIV’s previous
> >distributor in March 1999. The Alliance is now also  focusing on overseas
> >sales. SORAFIN After successful trials of SORAFIN in late 1999 established
> >its superiority   to the current most favoured treatment, directors are
> >scheduled to visit  International Pharmaceutical Companies to continue
> >discussions of co-ordinated  Stage III trials to satisfy regulatory
> >requirements here and overseas.  Trials in Australia, originally planned to
> >start earlier this year, will be  commenced after the overseas visit,  ""
> >disease because of its unpleasant appearance. As a result of
> >disappointment with current treatments many sufferers adopt a fatalistic
> >approach and do not seek any treatment. In the USA alone there are more
> >than 7  million sufferers, of whom a large majority do not use any of the
> >therapeutic  treatments available at present. Sorafin also has the
> >advantage of only sub-therapeutic levels of steroid  (0.01%) compared to
> >the higher levels of the favoured treatment (0.05% to 0.1%)  a very
> >important factor in treatment regimes, because of the side effects and
> >long term risks of long term use of higher dose steroids.  Yours Sincerely
> >John Walsh Managing Director
> Nigel McCarter
> Safety Management and Information Services Ltd
> Box 23 019 Hamilton
> Phone 64 7 858 2429 Fax 64 858 2689
> Mobile 02 212 4901
> 
> ----------------------------------------------------------------------------
> http://www.sharechat.co.nz/          New Zealand's home for market investors
> To remove yourself from this list, please us the form at
> http://www.sharechat.co.nz/forum.html.

----------------------------------------------------------------------------
http://www.sharechat.co.nz/          New Zealand's home for market investors
To remove yourself from this list, please us the form at
http://www.sharechat.co.nz/forum.html.